FRESENIUS SE+CO.KGAA O.N./ DE0005785604 /
08/11/2024 21:52:03 | Var. -0.100 | Volume | Denaro08/11/2024 | Lettera08/11/2024 | Capitalizzazione di mercato | Dividend Y. | Rapporto P/E |
---|---|---|---|---|---|---|---|
33.860EUR | -0.29% | 0 Fatturato: 0.000 |
-Quantità in denaro: - | -Quantità in lettera: - | 19.21 bill.EUR | - | - |
GlobeNewswire
23/04
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track R...
GlobeNewswire
23/02
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatm...
GlobeNewswire
04/09/2023
CIO Leadership: Generative AI and Visionary Leadership in the Enterprise Will Power the Discussion a...
GlobeNewswire
31/08/2023
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
GlobeNewswire
24/08/2023
CIO Leadership: The Steps Needed to Build a High-Performance Culture Will Power the Discussion at th...
GlobeNewswire
25/02/2022
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodia...
GlobeNewswire
05/01/2022
Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China)
GlobeNewswire
31/12/2021
CIO Leadership: HMG Strategy, the World’s #1 Executive Leadership Network, Looks Ahead to its 15th Y...
GlobeNewswire
09/12/2021
Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surge...
GlobeNewswire
22/11/2021
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
GlobeNewswire
22/11/2021
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology